Skip secondary menu

NINDS Wilson Disease Information Page


Table of Contents (click to jump to sections)


Listen to this page using ReadSpeaker


What is Wilson Disease?

Wilson disease (WD) is a rare inherited disorder of copper metabolism in which excessive amounts of copper accumulate in the body.  The buildup of copper leads to damage in the liver, brain, and eyes.  Although copper accumulation begins at birth, symptoms of the disorder only appear later in life.  The most characteristic sign of WD is the Kayser-Fleisher ring – a rusty brown ring around the cornea of the eye that can best be viewed using an ophthalmologist’s slit lamp. The primary consequence for most individuals with WD is liver disease, appearing in late childhood or early adolescence as acute hepatitis, liver failure, or progressive chronic liver disease in the form of chronic active hepatitis or cirrhosis of the liver.  In others, the first symptoms are neurological, occur later in adulthood, and commonly include slurred speech (dysarthria), difficulty swallowing (dysphagia), and drooling.  Other symptoms may include tremor of the head, arms, or legs; impaired muscle tone, and sustained muscle contractions that produce abnormal postures, twisting, and repetitive movements (dystonia); and slowness of movements (bradykinesia).  Individuals may also experience clumsiness (ataxia) and loss of fine motor skills.  One-third of individuals with WD will also experience psychiatric symptoms such as an abrupt personality change, bizarre and inappropriate behavior, depression accompanied by suicidal thoughts, neurosis, or psychosis.  WD is diagnosed with tests that measure the amount of copper in the blood, urine, and liver. 

Is there any treatment?

WD requires lifelong treatment, generally using drugs that remove excess copper from the body and prevent it from re-accumulating.  Zinc, which blocks the absorption of copper in the stomach and causes no serious side effects, is often considered the treatment of choice. Penicillamine and trientine are copper chelators that increase urinary excretion of copper; however, both drugs have some side effects.  Tetrathiomolybdate is an investigational copper chelating drug with a lower toxicity profile, but it has not been approved by the Food and Drug Administration for the treatment of WD and its long-term safety and effectiveness aren’t known.  A low-copper diet is also recommended, which involves avoiding mushrooms, nuts, chocolate, dried fruit, liver, and shellfish.  In rare cases where there is severe liver disease, a liver transplant may be needed.  Symptomatic treatment for symptoms of muscle spasm, stiffness, and tremor may include anticholinergics, tizanidine, baclofen, levodopa, or clonazepam. 

What is the prognosis?

Early onset of the disease may foretell a worse prognosis than later onset.  If the disorder is detected early and treated appropriately, an individual with WD can usually enjoy normal health and a normal lifespan.  If not treated, however, WD can cause brain damage, liver failure, and death.  The disease requires lifelong treatment. 

What research is being done?

The National Institute of Neurological Disorders and Stroke, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and other institutes of the National Institutes of Health (NIH) conduct and/or support research related to Wilson disease.  Growing knowledge of the copper transporting gene ATP7B, which in its mutated form causes WD, should lead to the design of better therapies for this disorder. 

NIH Patient Recruitment for Wilson Disease Clinical Trials

Organizations

Column1 Column2
American Liver Foundation
39 Broadway, Suite 2700
New York, NY   10006
info@liverfoundation.org
http://www.liverfoundation.org
Tel: 800-GO LIVER (465-4837) 212-668-1000
Fax: 212-483-8179

March of Dimes
1275 Mamaroneck Avenue
White Plains, NY   10605
askus@marchofdimes.com
http://www.marchofdimes.com
Tel: 914-997-4488 888-MODIMES (663-4637)
Fax: 914-428-8203

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health, DHHS
31 Center Drive, Rm. 9A06 MSC 2560
Bethesda, MD   20892-2560
http://www.niddk.nih.gov
Tel: 301-496-3583 TTY: 866-569-1162

Wilson Disease Association
5572 N. Diversey Blvd.
Milwaukee, MI   53217
info@wilsonsdisease.org
http://www.wilsonsdisease.org
Tel: 414-961-0533 866-961-0533
Fax: 414-962-3886



Prepared by:
Office of Communications and Public Liaison
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Bethesda, MD 20892



NINDS health-related material is provided for information purposes only and does not necessarily represent endorsement by or an official position of the National Institute of Neurological Disorders and Stroke or any other Federal agency. Advice on the treatment or care of an individual patient should be obtained through consultation with a physician who has examined that patient or is familiar with that patient's medical history.

All NINDS-prepared information is in the public domain and may be freely copied. Credit to the NINDS or the NIH is appreciated.

Last updated June 14, 2012